January 14, 2026

@michaelokun

Azathioprine and early Parkinson’s: new randomized study tests the immune hypothesis. Randomized means participants were assigned by chance. Double blind means neither participants nor health care providers knew who received the drug. Placebo controlled means results were compared to an inactive pill. Phase 2 means an early study designed to look for signals of benefit and safety. Greenland and colleagues describe a new paper in The Lancet Neurology as to whether azathioprine, an immune suppressing medication, could slow progression in early Parkinson’s disease. Key points: - Azathioprine was safe and generally well tolerated in folks w/ early Parkinson’s disease over the period of 12 months. - The study did not meet its primary goal of slowing progression on gait and balance related motor scores. - Exploratory signals suggested possible benefits in daily motor function and immune markers, particularly in some subgroups. My take: This is a humbling study. The results remind us that targeting biology beyond dopamine can be challenging. Immune modulation remains compelling, however broad immune suppression may not be the final answer. The signals in specific groups and biomarkers may point the field toward smarter and more precise next steps. Here are 5 points that resonated w/ me: 1- Parkinson’s disease clearly involves the immune system and this trial shows immune based studies are feasible. 2- Safety matters and this study should reassure health care providers that carefully monitored immune approaches can be tested. 3- Not hitting the primary outcome does not mean complete failure, it means we learned where the signal was weak and where it may be stronger. 4- Differences seen in some female participants suggested the possibility of sex specific biology. 5- Could the future lie in targeted immune strategies matched to the right folks at the right disease stage, rather than one size fits all? Or should we pivot away from this approach? https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00386-2/fulltext #michaelokun #fixelinstitute #parkinson #immunesystem